Literature DB >> 15588761

Synergistic interaction between ketoconazole and several antidepressant drugs with allopregnanolone treatments in ovariectomized Wistar rats forced to swim.

Miguel Molina-Hernández1, Norma Patricia Tellez-Alcántara, Julían Pérez García, Jorge Ivan Olivera Lopez, M Teresa Jaramillo.   

Abstract

This article was aimed to investigate the interest of the combination allopregnanolone plus ketoconazole in depression with the time-sampling method in the forced swimming task. Dose-response curves for fluoxetine (0.5, 1.0 or 2.0 mg/kg, twice day, during 2 weeks; i.p.), desipramine (0.5, 1.0 or 2.14 mg/kg, twice a day, during 2 weeks; i.p.), ketoconazole (6.25, 12.5, 25.0 and 37.5 mg/kg, once a day, during 2 weeks; i.p.) and allopregnanolone (0.5, 1.5, 2.0 mg/kg; once a day, during 2 weeks; s.c.) were established. Fluoxetine (1.0 mg/kg, p < 0.05; 2.0 mg/kg, p < 0.05) or ketoconazole (25.0 mg/kg, p < 0.05; 37.5 mg/kg, p < 0.05) produced antidepressant-like behavioral changes in swimming, highlighting a serotonergic mechanism while desipramine (1.0 mg/kg, p < 0.05; 2.14 mg/kg, p < 0.05) or allopregnanolone (1.5 mg/kg, p < 0.05; 2.0 mg/kg, p < 0.05) increased climbing behavior highlighting noradrenergic or dopaminergic effects. Subthreshold doses of fluoxetine (p < 0.05), desipramine (p < 0.05) or ketoconazole (p < 0.05) synergized with subthreshold doses of allopregnanolone and reduced immobility by increasing climbing. In conclusion, fluoxetine, desipramine, ketoconazole and allopregnanolone produced differential antidepressant-like actions in ovariectomized rats forced to swim. Ketoconazole, fluoxetine or desipramine synergized with allopregnanolone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588761     DOI: 10.1016/j.pnpbp.2004.08.006

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  6 in total

Review 1.  Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action.

Authors:  Veska Uzunova; Luther Sampson; Doncho P Uzunov
Journal:  Psychopharmacology (Berl)       Date:  2005-10-26       Impact factor: 4.530

Review 2.  The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders.

Authors:  Erin M MacKenzie; John Odontiadis; Jean-Michel Le Mellédo; Trevor I Prior; Glen B I Baker
Journal:  Cell Mol Neurobiol       Date:  2007-08       Impact factor: 5.046

3.  Quercetin mitigates Adriamycin-induced anxiety- and depression-like behaviors, immune dysfunction, and brain oxidative stress in rats.

Authors:  Sameha Merzoug; Mohamed Lamine Toumi; Abdelkrim Tahraoui
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-20       Impact factor: 3.000

4.  The antidepressant-like effects of topiramate alone or combined with 17β-estradiol in ovariectomized Wistar rats submitted to the forced swimming test.

Authors:  Miguel Molina-Hernández; N Patricia Téllez-Alcántara; Jorge I Olivera-López; M Teresa Jaramillo
Journal:  Psychopharmacology (Berl)       Date:  2013-08-24       Impact factor: 4.530

5.  Ergosteryl 2-naphthoate, An Ergosterol Derivative, Exhibits Antidepressant Effects Mediated by the Modification of GABAergic and Glutamatergic Systems.

Authors:  Mingzhu Lin; Haijun Li; Yan Zhao; Enbo Cai; Hongyan Zhu; Yugang Gao; Shuangli Liu; He Yang; Lianxue Zhang; Guosheng Tang; Ruiqing Wang
Journal:  Molecules       Date:  2017-03-31       Impact factor: 4.411

6.  Modulation of muscarinic system with serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice.

Authors:  Paramdeep Singh; Thakur Gurjeet Singh
Journal:  Indian J Pharmacol       Date:  2015 Jul-Aug       Impact factor: 1.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.